Infantile hemangioma. Part 2: Management

Area of Science:

• Dermatology
• Pediatric Medicine
• Pharmacology

Background:

• Infantile hemangiomas (IH) are common vascular tumors in infants.
• While many resolve spontaneously, some require intervention to prevent complications.
• Recent advancements have significantly improved IH management.

Purpose of the Study:

• To review current management strategies for infantile hemangiomas.
• To highlight the impact of propranolol on IH treatment.
• To discuss emerging therapies and diagnostic approaches for IH.

Main Methods:

• Literature review of recent studies on infantile hemangioma treatment.
• Analysis of clinical guidelines and expert recommendations.
• Discussion of pharmacological and procedural interventions.

Main Results:

• Propranolol is a revolutionary treatment for IH, often initiated outpatient at 1 mg/kg twice daily.
• Early specialist review (before 5 weeks) is crucial to prevent sequelae.
• Alternative treatments include corticosteroids, sirolimus, topical timolol, and laser therapy.
• Telemedicine is effective for IH diagnosis and management, with algorithms guiding remote care.

Conclusions:

• Propranolol has transformed infantile hemangioma management.
• Timely intervention and specialist care are vital for optimal outcomes.
• Telemedicine offers a viable approach for IH management, especially during pandemics.